Michael J. Newman

Michael J. Newman

Company: Indaptus Therapeutics

Job title: Founder & Chief Scientific Officer

Seminars:

Panel Discussion: What is the Best Modality & Delivery Approach to PRR-Pathway Targeting? 1:30 pm

Discussing safety profiles, dosing and scheduling considerations, therapeutic window Dissecting drug design approach for systemic and intratumoral Understanding possible regulatory considerations Mechanisms of action that are leading to strong efficacy Enhancing administration and delivery of therapies for safe and effective clinical outcomes Systemic delivery technologies vs intra-tumoral delivery technologiesRead more

day: Day Two

Eradication of Established Tumors with Induction of Innate & Adaptive Immunological Memory in Multiple Preclinical Models with Systemically Administered Decoy Bacteria, a Multi-TLR Agonist Therapeutic Vaccine 11:30 am

Explore how attenuated and killed, non-pathogenic, Gram-negative (Decoy) bacteria can induce potent priming of innate and adaptive anti-tumor immunity See how Decoy bacteria can produce single agent activity and safe tumoreradicating synergy with each of several different classes of immuno-oncology agents Decoy bacteria can also produce safe, single agent activity against chronic viral infections, including…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.